The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

Carboplatin

Intravenous carboplatin infusion every 3 weeks.

Trial Locations (1)

SM2 5PT

Institute of Cancer Research and Royal Marsden Hospital, Sutton

All Listed Sponsors
collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

European Research Council

OTHER

collaborator

Imperial College Healthcare NHS Trust

OTHER

collaborator

Dartford and Gravesham NHS Foundation Trust

UNKNOWN

collaborator

Maidstone & Tunbridge Wells NHS Trust

OTHER

collaborator

East and North Hertfordshire NHS Trust

OTHER_GOV

collaborator

Royal Free Hampstead NHS Trust

OTHER

collaborator

Buckinghamshire Healthcare NHS Trust

OTHER

collaborator

Barts & The London NHS Trust

OTHER

collaborator

Nottingham University Hospitals NHS Trust

OTHER

collaborator

Yeovil District Hospital NHS Foundation Trust

OTHER

collaborator

Northampton General Hospital NHS Trust

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER